Clinical Pharmacology and Drug Toxicity — MCQs

Clinical Pharmacology and Drug Toxicity Indian Medical PG Practice Questions and MCQs

Question 321: Tacrolimus acts by inhibiting which of the following?

A. DNA and RNA synthesis
B. Anti-lymphocyte antibody formation
C. T-cell proliferation (Correct Answer)
D. All of the above

Explanation: ### Explanation **Correct Answer: C. T-cell proliferation** **Mechanism of Action:** Tacrolimus (FK506) is a potent **calcineurin inhibitor**. It works by binding to an intracellular protein called **FK-binding protein (FKBP-12)**. This complex then inhibits calcineurin, a phosphatase enzyme required for the activation of the transcription factor **NFAT** (Nuclear Factor of Activated T-cells). Without NFAT activation, the transcription of **Interleukin-2 (IL-2)** and other cytokines is blocked. Since IL-2 is the primary growth factor for T-lymphocytes, its absence prevents **T-cell activation and proliferation**, leading to immunosuppression. **Why other options are incorrect:** * **Option A:** Drugs like **Azathioprine** (purine synthesis inhibitor) and **Mycophenolate Mofetil** (IMPDH inhibitor) act by inhibiting DNA/RNA synthesis. Tacrolimus acts on signaling pathways, not direct nucleotide synthesis. * **Option B:** Anti-lymphocyte antibodies (like ATG or Muromonab-CD3) are exogenous proteins used for induction therapy; Tacrolimus does not inhibit the formation of these antibodies. * **Option D:** Since Tacrolimus is highly specific for the calcineurin-NFAT pathway, it does not broadly target all the mechanisms mentioned. **NEET-PG High-Yield Pearls:** * **Potency:** Tacrolimus is 10–100 times more potent than Cyclosporine. * **Side Effects:** Unlike Cyclosporine, Tacrolimus is **more likely to cause Post-Transplant Diabetes Mellitus (PTDM)** and neurotoxicity (tremors), but **less likely** to cause hirsutism or gum hyperplasia. * **Monitoring:** Therapeutic Drug Monitoring (TDM) is essential due to its narrow therapeutic index. * **Drug Interactions:** It is metabolized by **CYP3A4**; inhibitors (like Ketoconazole or Erythromycin) can lead to Tacrolimus toxicity.

Question 322: Which of the following chelating agents is a degradation product of Penicillin?

A. EDTA
B. Dimercaprol
C. Penicillamine (Correct Answer)
D. Desferrioxamine

Explanation: **Explanation:** **Penicillamine** is the correct answer because it is a degradation product of **Penicillin**. Chemically, it is β,β-dimethylcysteine. It was first isolated from the urine of patients with liver disease who were receiving penicillin therapy. It contains a sulfhydryl (-SH) group that allows it to form stable, soluble complexes with heavy metals, which are then excreted by the kidneys. **Analysis of Options:** * **EDTA (Ethylene Diamine Tetra-acetic Acid):** A synthetic polyamino carboxylic acid. It is the primary chelator for **Lead poisoning** (given as Calcium Disodium EDTA to prevent hypocalcemia). * **Dimercaprol (BAL - British Anti-Lewisite):** A synthetic dithiol compound developed during WWII as an antidote for arsenic-based gas. It is used for **Arsenic, Mercury, and Lead** poisoning. * **Desferrioxamine:** A natural product derived from the bacterium *Streptomyces pilosus*. It is a specific siderophore used for **Acute Iron poisoning** and chronic iron overload (Thalassemia). **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Penicillamine is the drug of choice for **Wilson’s Disease** (Copper poisoning) and is also used in Cystinuria and severe Rheumatoid Arthritis. * **Adverse Effects:** It is notorious for causing **nephrotic syndrome**, membranous glomerulonephritis, and skin elastolysis (Cutis laxa). * **Pyridoxine Deficiency:** Penicillamine acts as a Vitamin B6 antagonist; supplementation is often required during long-term therapy. * **Contraindication:** Avoid in patients with a history of penicillin allergy (cross-reactivity risk).

Question 323: Which vitamin, in high doses, can cause macular edema and macular cyst?

A. Vitamin A
B. Vitamin D
C. Vitamin E
D. Niacin (Correct Answer)

Explanation: **Explanation:** **Correct Answer: D. Niacin (Vitamin B3)** Niacin, specifically in high doses used for treating dyslipidemia (usually >1.5g/day), can lead to a unique ocular toxicity known as **Niacin-induced Maculopathy**. This condition is characterized by the development of **cystoid macular edema (CME)**. The underlying mechanism involves the accumulation of fluid within the retinal layers, forming macular cysts. A key clinical feature that distinguishes this from other forms of CME is that it is typically **"angiographically silent"**—meaning there is no leakage of dye on Fluorescein Angiography (FFA), as the fluid accumulation is intracellular or due to Müller cell dysfunction rather than vascular leakage. The condition is reversible upon discontinuation of the drug. **Why other options are incorrect:** * **Vitamin A:** Chronic toxicity (Hypervitaminosis A) typically causes systemic features like dry skin, hepatosplenomegaly, and **idiopathic intracranial hypertension (pseudotumor cerebri)**, which leads to papilledema (optic disc swelling), not macular cysts. * **Vitamin D:** Toxicity primarily leads to hypercalcemia, which can cause **band keratopathy** (calcium deposits in the cornea), but it does not cause macular edema. * **Vitamin E:** High doses are generally well-tolerated but may interfere with Vitamin K metabolism, increasing the risk of bleeding; it has no known association with macular edema. **High-Yield Clinical Pearls for NEET-PG:** * **Niacin Flush:** The most common side effect of Niacin, mediated by **Prostaglandin D2** (prevented by Aspirin). * **Acanthosis Nigricans:** Can be a side effect of high-dose Niacin therapy. * **Differential for CME:** Other drugs causing Macular Edema include **Latanoprost** (Prostaglandin analogs), **Epinephrine**, and **Tamoxifen**. * **Niacin and Diabetes:** Niacin can cause hyperglycemia and should be used cautiously in diabetic patients.

Question 324: Chromodacryorrhea (shedding of pink tears due to accumulation of porphyrin) may be seen in poisoning with:

A. Arsenic
B. Barbiturate
C. Copper sulfate
D. Organophosphorus (Correct Answer)

Explanation: **Explanation:** **Chromodacryorrhea** (literally "colored tear flow") is a clinical sign characterized by the secretion of reddish-brown or pink tears. This occurs due to the excessive accumulation of **porphyrin** in the Harderian gland (a gland located behind the eyeball in certain mammals, though the term is used clinically in toxicology to describe similar cholinergic hypersecretion). 1. **Why Organophosphorus (OP) is correct:** OP compounds inhibit the enzyme **Acetylcholinesterase**, leading to an accumulation of Acetylcholine (ACh) at the synapses. This results in massive overstimulation of the parasympathetic nervous system (Muscarinic effects). One specific manifestation of this cholinergic crisis is the hypersecretion of exocrine glands. In OP poisoning, the stimulation of the lacrimal and Harderian-like structures leads to the shedding of porphyrin-rich "pink tears." 2. **Why other options are incorrect:** * **Arsenic:** Poisoning typically presents with "raindrop pigmentation," Aldrich-Mees lines on nails, and garlic breath, but not chromodacryorrhea. * **Barbiturates:** These are CNS depressants. Toxicity presents with coma, hyporeflexia, and "bullous lesions" (barb blisters), but does not cause hypersecretion. * **Copper Sulfate:** Toxicity is characterized by metallic taste, blue-green vomitus (hemolysis), and "Vomiting of blue vitriol," not pink tears. **NEET-PG High-Yield Pearls:** * **DUMBELS Mnemonic:** Remember the muscarinic features of OP poisoning: **D**iaphoresis/Diarrhea, **U**rination, **M**iosis, **B**ronchospasm/Bradycardia, **E**mesis, **L**acrimation (including Chromodacryorrhea), and **S**alivation. * **Management:** The specific antidote is **Atropine** (reverses muscarinic symptoms) and **Pralidoxime (2-PAM)** (reactivates the enzyme if given before "aging" occurs). * **Diagnosis:** Confirmed by measuring low levels of **Pseudocholinesterase** (Plasma cholinesterase) or RBC cholinesterase.

Question 325: What is the recommended dose of pralidoxime in organophosphate poisoning?

A. 1-2 mg IV
B. 1-2 mg IM
C. 1-2 g IV (Correct Answer)
D. 1-2 g oral

Explanation: **Explanation:** **1. Why Option C is Correct:** Pralidoxime (2-PAM) is a **cholinesterase reactivator** used in organophosphate (OP) poisoning. OP compounds bind to the enzyme acetylcholinesterase (AChE), leading to a "cholinergic crisis." Pralidoxime works by removing the phosphate group from the enzyme, thereby regenerating active AChE [2, 3]. To achieve therapeutic plasma concentrations rapidly and reverse neuromuscular blockade (especially respiratory muscle paralysis), a high dose of **1-2 g administered via slow Intravenous (IV) infusion** (usually over 15–30 minutes) is required [1]. **2. Why Other Options are Incorrect:** * **Options A & B (1-2 mg):** This dose is far too low. 1-2 mg is the typical starting dose for **Atropine** in OP poisoning, not Pralidoxime. Confusing the milligram dose of atropine with the gram dose of oximes is a common examiner trap. * **Option D (Oral):** In acute OP poisoning, the patient often has altered sensorium, vomiting, or severe respiratory distress. Oral administration is too slow and unreliable for an emergency antidote. **3. High-Yield Clinical Pearls for NEET-PG:** * **The "Aging" Phenomenon:** Pralidoxime must be administered early (ideally within 24–48 hours). Once the enzyme-toxin bond "ages" (dealkylation), oximes can no longer reactivate the enzyme [2, 3]. * **Atropine vs. Oximes:** Atropine reverses **muscarinic** symptoms (miosis, bradycardia, secretions) but does **not** fix muscle weakness. Pralidoxime is essential to reverse **nicotinic** effects (muscle paralysis). * **Rule of Therapy:** "Atropinize" the patient first (dry secretions/clear lungs) before or alongside oxime administration. * **Contraindication:** Oximes are generally **not** recommended for Carbamate poisoning as the enzyme-carbamate bond reverses spontaneously and oximes may worsen toxicity in certain cases (e.g., Carbaryl).

Question 326: Which of the following parameters should be monitored when a patient is on Magnesium sulfate therapy?

A. Deep tendon reflexes
B. Pulse rate (Correct Answer)
C. Respiratory rate
D. Urine output

Explanation: **Explanation:** Magnesium sulfate ($MgSO_4$) is the drug of choice for managing seizures in eclampsia. However, it has a narrow therapeutic index, and toxicity can lead to neuromuscular blockade and cardiac arrest. **Why Pulse Rate is the Correct Answer:** While all options listed are part of the clinical monitoring protocol for $MgSO_4$, the question asks for the parameter that is **NOT** typically a primary indicator of early toxicity or a standard prerequisite for the next dose. In clinical practice and standard textbooks (like Ghai or Williams Obstetrics), the "triad" of monitoring for $MgSO_4$ toxicity includes: 1. **Deep Tendon Reflexes (Patellar reflex):** The first sign of toxicity (disappears at 7–10 mEq/L). 2. **Respiratory Rate:** Depression occurs as levels rise (>12 breaths/min is required). 3. **Urine Output:** Magnesium is excreted solely by the kidneys; low output (<30 ml/hr) leads to drug accumulation. **Pulse rate**, while monitored as part of general vitals, is not a specific or early indicator of magnesium toxicity. Bradycardia and cardiac arrest only occur at extremely high, terminal levels (>15 mEq/L). **Analysis of Options:** * **A, C, & D:** These are the mandatory clinical "safety checks." If reflexes are absent, RR is <12, or urine output is low, the next dose must be withheld. * **B (Correct):** Pulse rate is the "odd one out" as it does not reliably predict impending magnesium toxicity compared to the others. **High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Range:** 4–7 mEq/L. * **First sign of toxicity:** Loss of Patellar reflex (Knee jerk). * **Antidote:** 10% Calcium Gluconate (10 ml IV over 10 minutes). * **Mechanism:** It acts as a CNS depressant and blocks neuromuscular transmission by inhibiting acetylcholine release.

Question 327: Which of the following is not used in the management of barbiturate poisoning?

A. Flumazenil (Correct Answer)
B. Alkaline diuresis
C. Hemodialysis
D. Activated charcoal

Explanation: **Explanation:** The correct answer is **Flumazenil** because it is a specific competitive antagonist at the GABA-A receptor benzodiazepine (BZD) binding site. While both barbiturates and benzodiazepines enhance GABAergic neurotransmission, they act at different sites on the receptor. **Flumazenil does not antagonize barbiturates**; it is exclusively used for benzodiazepine overdose. **Analysis of Options:** * **Alkaline Diuresis:** This is a mainstay for long-acting barbiturates (e.g., Phenobarbital). Since phenobarbital is a weak acid, alkalinizing the urine with Sodium Bicarbonate ($NaHCO_3$) promotes its ionization, preventing renal tubular reabsorption and enhancing excretion (ion trapping). * **Hemodialysis:** This is indicated in severe barbiturate poisoning, especially when the patient is in deep coma, has renal failure, or when conservative management fails. It is highly effective for removing long-acting barbiturates. * **Activated Charcoal:** Multiple-dose activated charcoal (MDAC) is used to interrupt the enterohepatic and entero-gastric circulation of barbiturates, significantly increasing their clearance. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Death:** In barbiturate poisoning, death usually occurs due to **respiratory failure** or cardiovascular collapse. * **Barbiturate vs. BZD:** Barbiturates increase the *duration* of GABA-gated chloride channel opening, whereas BZDs increase the *frequency*. * **Contraindication:** Forced alkaline diuresis is **not** effective for short-acting barbiturates (e.g., Thiopental) because they are primarily metabolized by the liver, not excreted by the kidneys. * **Specific Antidote:** There is **no specific pharmacological antagonist** for barbiturates; management is primarily supportive.

Question 328: A 4-year-old child, who has been playing with painted toys for the past 2 years and habitually places them in their mouth, develops drowsiness, fever, constipation, and abdominal pain 6 hours after exposure. What is the treatment of choice for this condition?

A. EDTA + Dimercaprol (Correct Answer)
B. DMSA
C. D-Penicillamine
D. BAL

Explanation: ### Explanation **Diagnosis: Acute Lead Encephalopathy** The clinical presentation of a child with a history of pica (mouthing painted toys), abdominal pain (lead colic), constipation, and neurological symptoms (drowsiness, fever) strongly suggests **Acute Lead Poisoning** with **Encephalopathy**. #### 1. Why EDTA + Dimercaprol is Correct In cases of **severe lead poisoning** (Blood Lead Levels >70 µg/dL) or when **encephalopathy** is present, a combination of two chelators is mandatory. * **Dimercaprol (BAL)** is given first because it can cross the blood-brain barrier and mobilize lead from the CNS. * **Ca-Na₂EDTA** is added 4 hours later to facilitate the excretion of the mobilized lead. * *Note:* BAL must be administered before EDTA to prevent EDTA from transiently increasing lead levels in the brain, which could worsen encephalopathy. #### 2. Why Other Options are Incorrect * **B. DMSA (Succimer):** This is the drug of choice for **asymptomatic** lead poisoning or moderate cases (BLL 45–69 µg/dL) without encephalopathy. It is administered orally. * **C. D-Penicillamine:** Used primarily for Wilson’s disease and sometimes as a third-line agent for lead poisoning, but it is not the treatment of choice for acute encephalopathy. * **D. BAL (Dimercaprol) alone:** While BAL is part of the regimen, it is insufficient on its own for lead; it must be combined with EDTA to ensure effective systemic clearance. #### 3. High-Yield Clinical Pearls for NEET-PG * **Lead Poisoning (Plumbism):** Look for "Burtonian lines" (bluish-purple gingival lines) and "Basophilic stippling" on peripheral blood smears. * **X-ray finding:** "Lead lines" at the metaphyses of long bones in children. * **Chelator of choice for other metals:** * **Iron:** Deferoxamine * **Copper/Wilson’s:** D-Penicillamine (or Trientine) * **Mercury/Arsenic:** Dimercaprol (BAL) or DMSA * **Iron Overload (Oral):** Deferasirox

Question 329: Vitamin B6 deficiency is seen with the use of all of the following drugs except:

A. Cycloserine
B. Cyclosporine (Correct Answer)
C. Isoniazid
D. D-Penicillamine

Explanation: **Explanation:** The correct answer is **Cyclosporine**. Vitamin B6 (Pyridoxine) deficiency occurs when drugs either interfere with its metabolic activation to Pyridoxal-5-Phosphate (PLP) or form complexes with it, leading to increased urinary excretion. **Why Cyclosporine is the correct answer:** Cyclosporine is a calcineurin inhibitor used as an immunosuppressant. Its primary toxicities are **nephrotoxicity**, hypertension, neurotoxicity (tremors), and gingival hyperplasia. It does **not** interfere with Vitamin B6 metabolism. **Why the other options are incorrect:** * **Isoniazid (INH):** This is the most classic cause. INH inhibits the enzyme *pyridoxine phosphokinase* and also reacts with PLP to form a hydrazone complex, which is excreted in the urine. This leads to peripheral neuropathy. * **Cycloserine:** An antitubercular drug that acts as a structural analog of D-alanine. It inhibits the enzymes that convert pyridoxine to its active form, often causing CNS side effects (seizures, psychosis) that are reversible with B6. * **D-Penicillamine:** Used in Wilson’s disease and rheumatoid arthritis, it chemically combines with pyridoxine to form a thiazolidine derivative, rendering the vitamin inactive and promoting its excretion. **NEET-PG High-Yield Pearls:** 1. **Hydralazine** (antihypertensive) is another high-yield drug that causes B6 deficiency and peripheral neuropathy. 2. **Clinical Presentation:** B6 deficiency typically manifests as **peripheral neuropathy**, sideroblastic anemia, and seborrheic dermatitis. 3. **Prophylaxis:** Patients on Isoniazid (especially those with diabetes, alcoholism, or malnutrition) should receive **10–50 mg/day** of Pyridoxine to prevent neuropathy. 4. **L-Dopa Interaction:** Pyridoxine increases the peripheral decarboxylation of L-Dopa, reducing its availability to the brain (unless combined with Carbidopa).

Question 330: Which of the following drugs does NOT cause painful salivary glands?

A. Phenybutazone
B. Ambroxol (Correct Answer)
C. Clozapine
D. Iodides

Explanation: **Explanation:** The clinical phenomenon of painful swelling of the salivary glands (often referred to as **"drug-induced sialadenitis"** or "mumps-like syndrome") is a specific adverse effect associated with a limited number of pharmacological agents. **Why Ambroxol is the Correct Answer:** **Ambroxol** is a mucolytic agent used to facilitate the clearance of mucus in respiratory conditions. It acts by increasing the production of surfactant and thinning secretions. It is **not** associated with salivary gland enlargement or pain. In fact, most mucolytics have no significant effect on the structural integrity or inflammatory status of the salivary glands. **Analysis of Incorrect Options:** * **Iodides (Option D):** These are the most classic cause of "iodide mumps." High concentrations of iodine are secreted in saliva, leading to irritation, inflammation, and painful swelling of the parotid and submandibular glands. * **Phenylbutazone (Option A):** This NSAID is a well-documented cause of parotid gland enlargement. The mechanism is thought to be a hypersensitivity reaction or direct toxic effect on the glandular tissue. * **Clozapine (Option C):** While Clozapine is famous for causing **sialorrhea** (excessive salivation/drooling), it can also lead to painful parotid swelling in a small percentage of patients, likely due to autonomic imbalance or secondary infection from stasis. **NEET-PG High-Yield Pearls:** * **Sialadenitis-inducing drugs:** Remember the mnemonic **"IPOC"** — **I**odides, **P**henylbutazone, **O**xyphenbutazone, and **C**lozapine/Chlorpromazine. * **Guanethidine** and **Bretylium** (anti-hypertensives/anti-arrhythmics) can also cause parotid pain, especially during meals. * **Clozapine Paradox:** Despite being an anticholinergic, it causes profuse salivation (sialorrhea) due to its agonist action at M4 receptors and inhibition of the swallowing reflex.

Practice by Chapter

Principles of Clinical Pharmacology

Practice Questions

Therapeutic Drug Monitoring

Practice Questions

Drug Toxicity and Overdose

Practice Questions

Antidotes and Their Applications

Practice Questions

Management of Drug Poisoning

Practice Questions

Drug-Induced Liver Injury

Practice Questions

Drug-Induced Kidney Injury

Practice Questions

Drug-Induced Blood Dyscrasias

Practice Questions

Drug-Induced QT Prolongation

Practice Questions

Pharmacovigilance

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free